Chemotherapy with laparoscope-assisted continuous circulatory hyperthermic intraperitoneal perfusion for malignant ascites

Table 1 Clinical data of patients undergoing laparoscope-assisted CHIPC in gastric cancer complicated by malignant ascites

Case No.	Gender	Age (yr)	Disease course (d)	Ascite volume (mL) [free cancer cells (+/-)]	Diagnosis	Examination	Pathology
1	F	46	17	7000 (+)	GC	GSB	MAC
2	M	58	21	4500 (+)	PGC	PP	M-LDAC
3	F	73	18	6000 (-)	GC	GSB	MDAC
4	F	58	12	4000 (+)	PGC	PP	MAC
5	M	76	7	4800 (+)	PGC	GSB	LDAC
6	M	58	9	9000 (+)	PGC	PP	SRCC
7	F	45	12	7000 (-)	GC	GSB	LDAC
8	F	59	80	4000 (+)	PGC	PP	SRCC
9	M	60	21	4500 (+)	PGC	PP	LDAC
10	M	67	13	4800 (-)	PGC	PP	M-LDAC
11	F	61	15	5000 (+)	GC	GSB	LDAC
12	M	52	14	6000 (+)	PGC	PP	MAC
13	F	68	9	5500 (+)	PGC	PP	LDAC
14	F	45	5	5800 (+)	GC	GSB	SRCC
15	M	59	12	6000 (-)	PG	PP	LDAC
16	F	72	16	7200 (-)	PGC	GSB	M-LDAC

CHIPC: Circulatory hyperthermic intraperitoneal perfusion chemotherapy; GC: Gastric cancer; PGC: Postoperative gastric cancer; GSB: Gastroscopic biopsy; PP: Postoperative pathology; MAC: Mucinous adenocarcinoma; M-LDAC: Medium-low differentiated adenocarcinoma; SRCC: Signet ring cell cancer.